Short answer
Foghorn Therapeutics Inc. (FHTX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 2026 financial results for the quarter ended September 30, 2026 announced.
Foghorn Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for the quarter ended September 30, 2026 announced
- Press release contains the substantive financial figures and operating updates
- Investor focus: cash position, operating expenses, pipeline progress and financing runway in Exhibit 99.1
Item 7.01 · Regulation FD Disclosure
- November 2026 investor presentation furnished as Exhibit 99.2
- Presentation likely contains updated company, pipeline, or strategic information for investor meetings
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 collaboration revenue $83.5M vs $8.2M, including $74.1M cumulative catch-up from discontinued FHD-909 and SMARCA2 programs
- Net income $58.2M, or $0.80 diluted EPS, vs $15.8M loss and $0.25 loss per share in Q3 2025
- Cash, equivalents and marketable securities $156.2M, supporting runway into second half of 2029
- IBD program entering dose-range studies in Q4 2026, with potential first-in-human trials by end of 2027
- Selective EP300 degrader targeting an IND in 2027, focused on multiple myeloma and DLBCL
Item EX-99.2 · Exhibit EX-99.2
- Investor presentation outlines wholly owned pipeline spanning oncology, I&I, and induced-proximity programs
- Cash and equivalents $156.2M as of 09/30/2026, supporting runway into second half of 2029
- Selective EP300 degrader: IND targeted in 2027 for multiple myeloma and DLBCL
- Oral IBD small molecule: drug research formulation initiation in Q4 2026, FIH studies targeted by end of 2027
- Approximately 71.8M shares outstanding, including pre-funded warrants, as of 09/30/2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Foghorn Therapeutics Inc. 8-K filings
Get the next FHTX 8-K as it lands
Follow FHTX for push alerts, or ask the research agent what this filing means.